L04AL Neonatal fragment crystallizable receptor (FcRn) inhibitors Neonatal fragment crystallizable receptor (FcRn) inhibitors Neonatal fragment crystallizable receptor (FcRn) inhibitors Neonatal fragment crystallizable receptor (FcRn) inhibitors L4
Source: Wikipedia · CC BY-SA 4.0 Fuente: Wikipedia · CC BY-SA 4.0 · nombre de respaldo (en) 来源:维基百科 · CC BY-SA 4.0 · 回退名 (en) 來源:維基百科 · CC BY-SA 4.0 · 回退名 (en)
ATC level L4 · Search this class · Consumer categories
Active ingredients in this class
3 active ingredients 3 principios activos 3 个活性成分 3 個有效成分
Each market now shows one aggregated status: a market counts as on sale if it has any active record; individual record statuses are shown in the details. The same market can also have several registration records with different statuses, so each market appears only once here; that is a record fact, not a safety judgement.
A missing name is marked in its row only when it is the exception; when most names lack it, the list stays unmarked.
- Rozanolixizumab
L04AL02active US GB CA AU ES · and 5 more y 5 más 另有 5 个 另有 5 個
active US GB CA AU ES TW EU FR · unknown HK - Efgartigimod Alfa
L04AL01active US GB CA SG ES · and 4 more y 4 más 另有 4 个 另有 4 個
active US GB CA SG ES EU FR · unknown AU - Nipocalimab
L04AL03active US GB CA EU · and 2 more y 2 más 另有 2 个 另有 2 個
active US GB CA EU · discontinued ES
By dosage form, across markets
Only ingredients with a recorded ATC class are listed (6,009 of 12,637).